Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 13, 2019Discontinuation of studies based on Data Safety Monitoring Board recommendation
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") today announced...
-
Jul 11, 2019
In the news release, New Data in 2 Oral and 13 Poster Presentations about Eisai's Latest Dementia Pipeline, Including BAN2401, Elenbecestat and Lemborexant, to be Presented at Alzheimer's...
-
Jul 9, 2019New Research Center Focused on Immunotherapy for Dementia
Eisai Inc., the U.S. subsidiary of Eisai Co., Ltd., announced today the opening of its Eisai Center for Genetics Guided Dementia Discovery ("G2D2"), a new exploratory research facility located in...
-
Jun 25, 2019- Results of the FREEDOM Study (Study 342) presented at the 33rd International Epilepsy Congress (IEC)
Eisai Inc. today announced results from its FREEDOM Study (Study 342), a Phase III open-label study conducted in Japan and South Korea evaluating the efficacy and safety of FYCOMPA® (perampanel)...
-
Jun 13, 2019-Results from the FREEDOM study, evaluating seizure freedom rates of FYCOMPA in new onset patients, including analyses at the 4 mg/day dose
Eisai Inc. today announced that it will present new data for FYCOMPA® (perampanel) CIII, including FREEDOM study results and the final results of one of the pediatric studies that supported the...
-
Jun 11, 2019New Phase 1 study on investigational treatment explores safety of lemborexant in healthy adult and elderly populations, and those with mild obstructive sleep apnea
Eisai Inc. today announced data on the respiratory safety of investigational lemborexant with multiple and single dosing in healthy adult and elderly individuals, as well as in those with mild...
-
Jun 11, 2019New analyses presented at SLEEP 2019 evaluated impact on key insomnia measures, including disease severity, sleep onset, sleep maintenance, and long-term safety, as well as next-day functioning
Eisai Inc. today announced new long-term safety and pooled analyses from the Phase 3 clinical development program for lemborexant, an investigational agent for sleep-wake regulation, currently...
-
May 28, 2019Data to be presented include:
Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") today announced eight poster presentations on lemborexant, an investigational agent being studied for the treatment of insomnia, a sleep-wake disorder,...
-
May 13, 2019
The Alzheimer's Clinical Trials Consortium (ACTC) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the investigational oral BACE (beta amyloid cleaving...
-
May 9, 2019-- Eisai presents key data from three retrospective real-world analyses at the 2019 American Academy of Neurology (AAN) Annual Meeting
Eisai Inc. presented the latest clinical results on FYCOMPA® (perampanel) CIII, at the 2019 American Academy of Neurology Annual Meeting in Philadelphia, including analyses highlighting the...